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Summary: One year after induction treatment, cryptococcal meningitis mortality reaches almost 80% in HIV-
infected cohorts and more than 70% of non-HIV and HIV-infected survivors live with impairments. Early 
therapeutic intervention and early management of disability could significantly improve prognosis. 
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Abstract :  
Cryptococcal meningitis (CM) is the primary cause of meningitis in HIV-infected adults and an emerging 
disease in HIV-seronegative individuals. No literature review has studied the long-term outcome of CM.  We 
performed a systematic review on the long-term (≥3 months) impact of CM (C. neoformans and C. gattii) on 
mortality and disability in HIV-infected and non-HIV-infected adults. Though the quality of current evidence is 
limited, the long-term impact of CM on survival and disability appears to be high. One-year mortality ranged 
from 13% in an Australian non-HIV C. gattii infected cohort to 78% in a Malawian HIV-infected cohort treated 
with fluconazole monotherapy. One-year impairment proportions among survivors ranged from 19% in an 
Australian C. gattii cohort to more than 70% in a Taiwanese non-HIV and HIV-infected cohorts. Ongoing early 
therapeutic interventions, early detection of impairments and access to rehabilitation services may 
significantly improve patients’ survival and quality of life. 
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INTRODUCTION 
Cryptococcal meningitis (CM) is a leading cause of meningitis in many low and middle income countries 
(LMICs) where it accounts for 15-20% of all HIV-related mortality[1]. Despite the expansion of antiretroviral 
therapy (ART) programmes, rates of CM remain high as many HIV-infected persons start ART late and face 
difficulties maintaining effective treatment[2]. Moreover, sustainable access to the current reference 
induction treatment, flucytosine (5-FC) and amphotericin B (AmB), is a major challenge in these settings. 
Fluconazole monotherapy is the only alternative but is associated with higher short-term mortality, even at 
high dosages[3]. Consequently, CM mortality remains high in LMICs ranging from 19% to 96%[4,5] at 10-12 
weeks.  In contrast, it has been estimated to range from 9% to 15% in Western Europe and North 
America[6,7].  
Additionally, a growing number of CM-associated deaths occur in non-HIV patients in high-income countries 
(HIC)[8]. CM caused by C. neoformans, is increasingly observed among patients with non-HIV 
immunosuppression[8]. In parallel, C. gattii CM, endemic in Australia, appeared recently as an outbreak in 
North America, mainly among patients without apparent immunosuppression (up to 72% of cases). It appears 
that non HIV-associated CM (non-HIV-CM) mortality outcomes are no better than HIV-associated CM in 
similar settings [8].  
Beyond mortality, CM survivors may experience different long-term (≥3 months after CM diagnosis) 
neurological and sensorial impairment resulting into disability and poor quality of life[6,9].  
However, data on the long-term outcome of CM remain scarce [10,11]. Indeed, while short-term mortality of 
HIV-CM has been well reviewed [7,8,12,13], literature reviews including longer-term overall cryptococcosis 
mortality are limited[8,13] and none have reported long-term CM-related neuro-sensorial impairment and 
disability.   
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To address this gap, we exhaustively reviewed published data on the long-term mortality, impairment and 
disability following CM caused by C. neoformans or C. gattii occurring in either immunodeficient or 
immunocompetent adults. The following questions were addressed: what are the proportions/rates and 
predictive factors for mortality occurring ≥3 months after CM diagnosis or treatment induction? What are the 
nature, frequency and predictive factors of CM sequelae/impairment, disability and decreased quality of life 
occurring ≥3 months after CM treatment induction? Finally, are there differences in the ≥3 month prognosis 
between HIV and non-HIV infected patients?  
 
METHODS 
This systematic review was conducted in line with the PRISMA Statement[14]. 
Search strategy and study selection  
PubMed/Medline, Web of Science, Cochrane Library, Embase, Global Health, LILACS and WHO online libraries 
were searched for studies published in English, French and Spanish between Jan 1st, 2005 and June 30th, 2015 
(Figure 1). The search combined two groups of words including synonyms and MeSH terms of (group 1) 
“Cryptococcal Meningitis” and (group 2) “Outcome and risk factors” (see Supplementary Table 1).  
All types of study design were considered for eligibility. Studies were included if they fulfilled the following 
criteria: 1) reporting the mortality rate/proportion and/or the proportion of sequelae/impairments/disability 
occurring ≥3 months after CM diagnosis or after induction treatment, 2) participants ≥18 years-old, 3) with 
documented first episode of CM diagnosed by positive India Ink and/or positive Cryptococcal Antigen and/or 
positive cerebrospinal fluid (CSF) culture (C. neoformans or C. gattii). Both immunodeficient and apparently 
immunocompetent patients were considered.  
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Studies on cryptococcomas without CM and studies where CM data could not be individualized from other 
causes of meningitis were excluded. Additional studies were manually searched for from reference lists of all 
identified articles.  
Quality assessment 
The quality of the selected studies was assessed at outcome level[14] using the Critical Appraisal Skills 
Programme (CASP) tools[15]. Domains assessed were: (1) validity: appropriate design, appropriate sampling 
methods, risk of bias and confounding; (2) importance: effect size, power, precision of the study; and (3) 
comparability/generalizability. Studies that fulfilled more than 70% of criteria were considered of good 
quality and those that fulfilled less than 50% of CASP criteria were excluded for providing weak evidence. 
Data extraction and synthesis 
For each study included, the following data were extracted: (1) study characteristics (setting, design, sample 
size, statistical method used, potential bias and confounding), (2) participants characteristics (eligibility 
criteria, age, sex, immunological, mental and ART status at diagnosis, ART timing of initiation), (3) 
Cryptococcus species, (4) outcome (mortality proportion/rate, impairments/disability proportions and quality 
of life) stratified by outcome timing (6, 12, >12 months after diagnosis) and (5) predictive factors (age, 
immunological status, viral load, CSF characteristics, clinical presentation, mental and ART status at diagnosis,  
antifungal and ART treatment received, adjunctive therapy, setting, cryptococcus species, Immune 
Reconstitution Inflammatory Syndrome (IRIS) occurrence, opportunistic co-infections/affections).  
Quality assessment of included studies showed high heterogeneity; therefore we decided to undertake a 
qualitative synthesis rather than a meta-analysis, which included describing the studies, their results and 
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limitations without pooling estimates. Further synthesis of the results was done with predefined sub-groups 
by the patients’ immunological status (HIV, non-HIV). 
 
RESULTS 
Study characteristics  
Of the 6035 records identified during the study period, 177 were selected for full-text review, and 25 articles 
(24 studies: four randomized clinical trials (RCT), eleven prospective cohorts and nine retrospective cohorts) 
were eventually retained (Figure 1). Only one of the studies[16] was included although not fulfilling the 
inclusion criteria, because it provided key results on disability. 
Twenty-one studies provided information on mortality outcomes, six on impairments, two on disability and 
none on quality of life. All continents were represented with fifteen studies from LMIC and nine from HIC. 
Only six (25%) studies fulfilled at least 70% of quality criteria: two RCT and four cohorts (Table 1). 
 
Long-term mortality and its predictive factors 
In HIV-CM, seventeen articles provided information on CM-mortality (five from HIC and twelve from LMIC), 
and ten examined risk factors (Table 2). Five (28%) articles fulfilled at least 70% of quality criteria. Available 
data suggest that the high mortality rate of the first ten weeks of treatment continues to rise slowly to level 
off after six months of treatment [16–19]. However, evidence was weak with few studies and difference in 
CM management across studies. Two studies using survival analysis showed that when using both AmB-based 
 8 
 
combination therapy and appropriately timed ART, the survival curve strongly flattens after 3 months[20,21].  
There was important variation in the one-year mortality according to both setting and period: in HIC, 
mortality was around 50% in the pre-ART period[22] and 20% in the late ART period[22–24], while it ranged 
from 39.5% to 78% in LMIC[17–21,25–27]. The one-year mortality also varied according to the induction 
treatment received with fluconazole performing worse than AmB monotherapies, which, in turn, performed 
worse than AmB-based combined therapy (Figure 2 and Table 3). Nevertheless, even with the latter, the one-
year mortality rate was around 40%[19,20] in LMIC and around 20%[22–24] in HIC. Other protective factors 
included the use of ART as shown in France[22] and Denmark[24], and, in ART-naïve patients, delaying the 
introduction of ART to 5 to 10 weeks after induction therapy compared to an introduction between 3 days to 
2 weeks[20,28]. In LMIC, the one-year mortality observed in patients receiving aggressive Intracranial 
Pressure (ICP) management was lower compared to those who did not (40%[19,20] versus 59%[18], 
respectively).  
In HIV-CM, the main independent risk factors for long-term mortality were altered neurological status[25,27], 
low CD4 level[23], high CSF fungal/CrAg burden[16,25], and older age[24] at diagnosis. Lastly, the evidence on 
an association between IRIS and higher long-term mortality is still unclear [20,29,30]  with only one study of 
the three that addressed this question showing a significant association[29]. This may result from the small 
study sizes or from the IRIS definition adopted which may miss early IRIS leading to an ascertainment bias, as 
suggested by Boulware et al(2014)[20]. 
 
In non-HIV-CM, evidence on long-term mortality is weaker as only six articles (none from LMIC) were 
identified and none fulfilled at least 70% of quality criteria (Table 2).  
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One-year mortality ranged from 13.7% in an Australian cohort infected by C. gattii with only 28% of patients 
with underlying conditions [11,31] to 42.3% in a Taiwanese study with all patients having underlying 
conditions[23]. Non-HIV-CM mortality may continue to rise after three months, as suggested by data from 
Liao et al. [23].  
The main independent risk factors for one-year mortality in non-HIV patients were delayed diagnosis[32], 
age>60 years[32], altered initial neurological status[23,32], high CSF CrAg[23] and non-AmB-based compared 
to AmB-based induction therapy[32] (Table 4). In patients with C gattii CM, only high CSF CrAg was found to 
be independently associated with one-year mortality[11]. 
 
Long-term neuro-sensorial impairments and disability and their predictive factors 
Seven studies provided evidence on neuro-sensorial impairment and disability (three for HIV-CM and four for 
non-HIV-CM) and only one fulfilled at least 70% of quality criteria[33] (supplementary Table 2).  
 
In HIV-CM, up to 69.2% of survivors from a Taiwanese cohort had neuro-sensorial sequelae[23], mainly 
residual headache (38%), motor deficit (15%) and vertigo (15%), one year after diagnosis. In a Ugandan study, 
cognitive function remained impaired in 41% of survivors, although the contribution of HIV encephalitis 
should also be questioned [33].  
Only two studies assessed the long-term disability related to HIV-CM [16,33] and none used the WHO 
International Classification of Functioning definition[9]. In the clinical trial of Day et al., 40% of the survivors 
reported having some form of “disability” at six months [16] and in the cohort study reported by Carlson et al. 
11% of the survivors declared themselves unable to work at one year [33].  
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Few predictive factors of long-term impairments and disability were found. Carlson et al. demonstrated that 
the risk of 12-month impaired cognition was increased in HIV-CM patients with lower CD4 level at induction. 
And paradoxically, persons with sterile CSF cultures after 14 days of AmB therapy had worse neurocognitive 
outcomes than those still culture-positive[33]. At six months, Day et al. demonstrated that patients treated 
with AmB+5-FC were half as likely to report having a “disability” than patients treated with AmB 
monotherapy[16]. 
 
In non-HIV-CM, findings were heterogeneous. In a cohort of patients infected with C. gattii without 
underlying conditions, the rates of neuro-sensorial sequelae among one-year survivors were between 19% 
and 24% [11,34]. This proportion reached 73.3% in a cohort of patients with underlying conditions 
(Cryptococcus species not known)[23]. The main impairments were vertigo (13% to 24%), visual loss (13% to 
23%), hearing impairment (6% to 17%), and motor deficit (3% to 16%). 
MRI sylvian fissure enhancement and CSF CrAg titres >1/256 at induction were, respectively, independently 
associated with hearing loss in any non-HIV-CM,[35] and  neurological sequelae in  C. gattii cohorts [11]. 
 
Comparison between HIV and non-HIV-CM 
The three studies comparing long-term mortality between HIV and non-HIV-CM[23,36,37] gave 
contradictory results. Nevertheless, the studies’ heterogeneity in terms of proportions of ART-naïve patients 
for HIV-CM and in terms of proportions of patients with underlying conditions for non-HIV-CM prevents any 
valid comparisons. 
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DISCUSSION 
 
Long-term impact of CM on mortality, impairments and disability 
To our knowledge, this is the first literature review focusing on long-term outcomes of CM, including 
mortality, neuro-sensorial impairment and disability. Our review shows that the mortality can reach rates up 
to 78% in HIV-CM[27] and 42% in non-HIV-CM[23] at one year. In addition, regardless of the species studied 
(C. neoformans, C gattii), we found supportive evidence for an important long-term burden of CM on 
impairments and disability with proportions reaching up to 70% in both HIV-infected and HIV-non-infected 
survivors[23]. These findings demonstrate that the long-term prognosis of CM in adults may be at least as 
poor as that associated with other aetiologies of encephalitis in France (33% with impairment at 3 
years)[38]or, that associated with tuberculosis meningitis (TBM) (20% to 60% of mortality and 20% to 50% of 
impairments among survivors)[39,40]. 
 
Prevention of risk factors of long-term adverse CM outcomes 
Evidence regarding risk factors for long-term outcomes was limited showing an important gap in knowledge. 
Each of the risk factors for long-term outcomes identified were found to be predictive in only 1 to 3 studies. 
Some studies did not adjust for confounders (ART[22] and IRIS[20,29] in HIV-CM patients, underlying 
conditions[11,32] and high CSF antigen titers[35] in non-HIV-CM patients). Some important potential 
predictive factors have not been studied (e.g. Cryptococcus species, phenotypes and genotypes, ICP 
management) and discordant results regarding the effect of IRIS in HIV-CM or of underlying conditions in non-
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HIV-CM were reported. Moreover, definitions of some risk factors varied according to studies (abnormal 
neurology, fungal burden assessment tools and threshold, underlying pathologies) limiting the potential for 
comparison. Therefore, future research should systematically assess the long-term impact of all these risk 
factors using standardized and validated definitions and tools. 
Nevertheless, some key actions can be identified to prevent long-term mortality, impairment and disability. 
In HIV-CM, some of the well-known short-term mortality risk factors (baseline altered neurology, high fungal 
burden or immunosuppression)[21] seem to be also predictive of long-term adverse outcomes. Their 
identification could orient clinicians in providing closer clinical follow-up. More importantly, our review 
identified some evidence for a protective effect of AmB-based combined antifungal regimens for long-term 
mortality and AmB+5FC therapy on long-term disability. In addition, it has to be noted that only 1/7[33] of the 
cohorts assessing impairments and disability in this review provided an AmB-based combined therapy to all 
patients. Moreover, while ART does not appear to influence short-term HIV-cryptococcosis mortality[41], it  
plays a key role in reducing long-term mortality[20,22,24,26,28,42]. As in TBM[43], if introduced 
appropriately (after 4-5 weeks), ART might protect against other opportunistic infections[20]. Therefore, in 
order to prevent not only short-term but also longer-term adverse outcomes, there is an urgent need to scale 
up access and coverage of ART, AmB and especially 5-FC therapy, usually not available in LMICs [44]. 
Additionally, future research on antifungal therapy, as well as adjuvant therapy (especially IRIS and ICP 
management), should assess the effect on long-term outcomes, including disability. 
In non-HIV-CM, the limited number of studies along with their heterogeneity preclude firm conclusion on 
long-term mortality risk factors. In C.gattii cohorts, our results suggest that underlying conditions and altered 
mental status at induction might be poor long-term prognostic factors[11,34]. But, these univariable 
associations might be confounded by other factors. For instance, experimental studies have shown that a 
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difference in virulence of the C.gattii genotype infecting Australian patients (mainly VGI)[45] compared to the 
one of Canadian patients (mainly VGII A)[46] might be another explanation for  the difference in mortality. In 
general, the identified risk factors of non-HIV-CM long-term mortality advocate for early CM diagnosis in 
people >60 years old with underlying conditions. Nevertheless, management guidelines are based on results 
from trials involving patients with HIV-CM that may not apply to those with non-HIV-CM. Further multi-
centric cohorts/trials, as already conducted for Solid Organ Transplant patients[47], should therefore be 
proposed, assessing further these potential predisposing factors and looking for the best therapeutic choice. 
 
Poor attention to impairment and disability  
Despite the fact that many studies were initially identified, few had quality data on long-term outcomes and 
only seven assessed long-term impairments and disability. Only three studies assessed impairments/disability 
and their predictive factors as a primary outcome and five did not describe the method of outcome 
measurement [11,23,31,34,36]. None used the WHO definition of disability[9], nor assessed quality of life. 
Similarly, reviews of long-term outcomes of other meningo-encephalitis causes identified a paucity of studies 
and very few data on morbidity and impairment[38,48]. This is indicative of the low value placed on the 
collection of long-term meningo-encephalitis outcomes, especially impairment/disability data. Very few 
studies conducted systematic screening for impairments with validated tools, which may lead to 
misclassifications and underreporting. Indeed, the two studies that systematically assessed the patients with 
validated tools found much higher proportions of impairments compared to the others (impaired cognition in 
41% of HIV-CM survivors[33] and hearing impairment in 31% of non-HIV-CM survivors[35]). Therefore, future 
CM research should not only focus on short-term medical outcomes, but also on longer-term impairments, 
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disability and quality of life. WHO definitions of disability[9] as well as validated neurocognitive, sensorial and 
quality of life assessment tools should be used as in studies of other forms of encephalitis[38,48].  
 
Implication for rehabilitation 
Despite the limited amount of evidence, it is alarming to see that at one year, 20% to 70% of survivors have 
long-term impairments limiting cognitive, motor, visual and/or hearing function in both HIV and non-HIV-CM 
patients in both LMICs and HICs. And, while research and guidelines focus mainly on the management of the 
acute phase of CM to prevent acute mortality[49], little attention is given to  long-term follow-up and the 
identification of, and support for, impairments and disability. Therefore, ensuring access to physical, 
occupational, sensorial and cognitive rehabilitation services is as important as enhancing prevention by 
fluconazole pre-emptive treatment and access to ART and AmB-based therapy[9]. While these services are 
routinely accessible in developed countries, they are limited in LMICs due to a lack of rehabilitation personnel 
and high costs[50]. For this reason, the development and adaptation of context specific rehabilitation models 
should be one of the global research priorities for CM and CNS infections, as already advocated by John et 
al.[50].  
 
Limitations 
In addition to the limitations related to the quality and heterogeneity of included studies, our review has 
some external limitations. Our inclusion and exclusion criteria might have restricted the panel of literature 
found. Eleven studies have been excluded because they included patients aged less than eighteen 
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(Supplementary Table 3). Moreover, the chosen threshold of quality is arbitrary as the CASP group has yet to 
propose a validated scoring system. This has led to exclusion of an additional eleven articles in order to 
decrease the risk of inaccurate conclusions (Supplementary Table 3). Nevertheless, each article excluded due 
to age or quality was carefully examined and its exclusion impact assessed. Subsequently, one article was 
then reintroduced in our review based on this assessment[16].  
 
CONCLUSION 
CM has an important long-term impact on mortality and disability. Nevertheless, the quality of evidence is 
limited, and future CM research should not only focus on short-term medical outcomes, but also on the 
longer-term mortality, impairments, disability and quality of life. In the meantime, fluconazole pre-emptive 
treatment, early diagnosis, as well as improved access to timely effective combined antifungal therapy should 
be implemented to prevent CM mortality and its long-term consequences. Additionally, early detection of 
impairments and access to rehabilitation services will improve CM-infected survivors’ quality of life.   
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TABLES:  
Table 1: Overview of the 25 articles included in this review 
 Article Setting Design Sample size - number 
Mean Age 
(except when 
mentioned) – 
years (IQR) 
Information on 
Morta
lity 
Seque
lae/I
mpair
ments 
Disabi
lity/q
uality 
of life 
HIV-CM 
1 
Bicanic 
(2008)[19] 
LMIC (South 
Africa) 
RCT 
64 
(30 in AmB 0.7mg arm, 34 
in AmB 1 mg arm) 
33 (28-38)    
2 Day (2013)[16] LMIC (Vietnam) RCT 
298 
(99 in AmB arm, 100 in 
AmB+5-FC arm, 99 in 
AmB+Fluconazole arm) 
Median: 28 (24-31) 
(Children 14-18 
years old included) 
   
3 
Makadzange 
(2010)[28] 
LMIC (Zimbabwe) RCT 
54 
(28 in early ART arm and 
26 in late ART arm) 
37 +/-7.7    
4 
Boulware 
(2014)[20] 
LMIC (South 
Africa)  
RCT 
177 
(88 in early ART arm and 
Median: 
Early ART:  35 (28-
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LMIC (Uganda) 89 in late ART arm) 40) 
Late ART: 36 (30-
40) 
5 
Kambugu 
(2008)[18] 
LMIC (Uganda) PC 
44 
36 (31-42)    
6 
Bicanic 
(2007)[26] 
LMIC (South 
Africa) 
PC 
54 
(36 ART Naïve, 18 ART 
experienced) 
34 (29-39)    
7 
Bicanic 
(2009)[29] 
LMIC (South 
Africa) 
PC 
100 
(65 survived for analysis 
on IRIS : 
11 in IRIS arm and 54 in 
non-IRIS arm)) 
>18 years    
8 
Boulware 
(2010)[30] 
LMIC (Uganda) PC 
101 
(56 in IRIS arm, 45 in non-
IRIS arm) 
?    
9 
Butler 
(2012)[17] 
LMIC (Uganda) PC 189 
 
36.2 (SD +/-8.8) 
   
1
0 
Rothe (2013)[27] LMIC (Malawi) PC 
60 
Median: 32 (29-39)    
1
1 
Chaiwarith 
(2014)[25] 
LMIC (Thailand) RC 
79 
35.1 +/-7.2    
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1
2 
Carlson 
(2014)[33] 
LMIC (Uganda) PC 78 35 +/-8    
1
3 
Lizarazo 
(2012)[36] 
LMIC (Columbia) RC 
63 
34 +/-9.2    
1
4 
Jarvis (2014)[21] 
LMIC (South 
Africa) 
PC 
263 
Median: 34 (29-39)    
1
5 
Lanoy (2011)[22] HIC (France) PC 1020 
<30y: 16% 
30-40: 50% 
40-50: 24% 
>50: 11% 
  
 
1
6 
Mathiesen 
(2012)[24] 
HIC (Denmark) RC 45 40 (33-46)   
 
1
7 
Cachay 
(2010)[42] 
HIC (USA) RC 82 38 (19-57)   
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 Article Setting 
Desig
n 
Sample size (number) Age (years) 
Information on 
Mortal
ity 
Sequ
elae/
Impai
rmen
ts 
Disabil
ity/qu
ality of 
life 
HIV and non-HIV-CM 
1
8 
Liao (2012)[23] HIC (Taiwan) RC 
HIV: 
19 
72 
non-
HIV: 
53 
HIV: 33.3 +/-7.4 
 
non-HIV: 55.3 +/-
15.7 
  
 
1
9 
Lee (2011)[37] HIC (Taiwan) RC 
HIV: 
37 
88 
non-
HIV: 
51 
HIV: 38.19 +/-
12.12 
 
non-HIV: 59.57 
+/-14.17 
  
 
Non-HIV-CM 
2
0 
Zhu (2010)[32] LMIC (China) RC 
154 Median: 38.5   
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2
1 
Wang 
(2005)[35] 
HIC (Taiwan) PC 26 
No Hearing loss 
group: 47 +/-21 
Hearing loss 
group:  
57 +/-17 
  
 
2
2 
Phillips 
(2015)[34] 
(C. gattii) 
HIC (British 
Columbia, Canada) 
RC 47 
Median: 50 
(range 21-89) 
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 Article Setting 
Desig
n 
Sample size (number) Age (years) 
Information on 
Mortal
ity 
Sequel
ae/ 
Impair
ments 
Disabil
ity/qu
ality of 
life 
2
3 
a
n
d 
2
4 
Chen 
(2012)[11] and 
(2013)[31] 
(C. gattii) 
HIC (Australia) RC 73 ?   
 
2
5 
Sun (2009)[51] 
HIC/MIC (USA, 
France, Spain, 
Canada, India) 
PC 75 51.5 (43-60)   
 
 
RCT: Randomized Control Trial, PC: Prospective Cohort, RC: Retrospective Cohort. 
HIC: High Income Countries.  LMIC: Low and Middle Income Countries 
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Table 2: Long-term mortality:  
Study Setting Design Sample 
size 
C gattii (CG) 
C neoformans(CN) 
Mortality % –[95% CI]
a
 (Numbers) 
(PD or SA)
b
 
Quality’s 
score 
HIV-CM 
>3months-4months after diagnosis or induction treatment 
Liao (2012)[23] HIC (Taiwan) RC 19 No data 5.3% (1/19) (PD) d90 54% 
Lee (2011)[37] HIC (Taiwan) RC 37 No data 29.7% (11/37) (PD) d90 58% 
Chaiwarith (2014)[25] LMIC (Thailand) RC 79 CN (92%)  32.4% (24/74) (PD) d90  65% 
Lizarazo (2012)[36] LMIC (Columbia) RC 63 CN 54%  (SA) d120 50% 
6 months after diagnosis or induction treatment 
Cachay (2010)[42] HIC (USA) RC 82 No data 6.1% (5/82) (PD) 64% 
                                                          
a No 95% CI mentioned if not available 
b PD: Mortality expressed as a Percentage of Death at the time point (lost to follow-up excluded when known), or  
SA: Survival Analysis (probability of mortality at a time point, lost to follow-up censored) 
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Bicanic (2008)[19] LMIC (South Africa) RCT 64 No data 32% (PD) 55% 
Boulware (2014)[20] LMIC (South Africa – 
Uganda) 
RCT 177 No data 37.9% (67/177) (PD) 82% 
Day (2013)[16] LMIC (Vietnam) RCT 298 CN (VNI) 45% (132/291) (PD)  82% 
Butler (2012)[17] LMIC (Uganda) PC 189 No data 52% [45-59] (SA) 58% 
Bicanic (2009)[29] LMIC (South Africa) PC 100 No data 53% (53/100) (PD) 54% 
Kambugu (2008)[18] LMIC (Uganda) PC 44 No data 59.1% (26/44) (PD) 73% 
1 year after diagnosis or induction treatment 
Lanoy (2011)[22] HIC (France) PC 1020 No data 50% [45-54] (SA) during the Pre-cART period: 92-95 
24% [18-29] (SA) during the Early cART period: 96-98 
17% [12-22] (SA)  during the Late cART period: 99-04 
64% 
Liao (2012)[23] HIC (Taiwan) RC 19 No data 22.2% (4/18) (PD) 54% 
Mathiesen (2012)[24] HIC (Denmark) RC 45 No data 44.2% (SA) during the full period 88-08 81% 
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23% (SA) during the cART period 97-08 
Boulware (2010)[30] LMIC (Uganda) PC 101 No data 27.7% (28/101) but first weeks deaths excluded 77% 
Boulware (2014)[20] LMIC (South Africa – 
Uganda) 
RCT 177 No data 39.5% (70/177) (PD) 82% 
Bicanic (2008)[19] LMIC (South Africa) RCT 64 No data 40% (PD) 55% 
Jarvis (2014)[21] LMIC (South Africa) PC 263 No data 41% (PD) 57% 
Chaiwarith (2014)[25] LMIC (Thailand) RC 79 No data 52.2% (36/69) (PD) 65% 
Butler (2012)[17] LMIC (Uganda) PC 189 No data 55% [38-52] (SA) 58% 
Kambugu (2008)[18] LMIC (Uganda) PC 44 No data 59.1% (26/44) (PD) 73% 
Bicanic (2007)[26] LMIC (South Africa) PC 54 No data 64.7% (33/51) (PD) 69% 
Rothe (2013)[27] LMIC (Malawi) PC 60 No data 78% [64-86] (SA) 69% 
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Study Setting Design Sample 
size 
C gattii 
C 
neoform 
Immune Status Mortality %age –[95% CI]
c
 
(Numbers) 
(PD or SA)
d
 
Quality’ 
score 
Non- HIV-CM 
>3months-4months after diagnosis or induction treatment 
Sun (2009)[51] HIC (USA, Canada, 
France, Spain) + India 
PC 75 No data 100% Solid Organ Transplant 18.7% (14/75) (PD) d90 69% 
Liao (2012)[23] HIC (Taiwan) RC 53 No data 100% with underlying conditions 30.8% (16/52) (PD) d90 54% 
Lee (2011)[37] HIC (Taiwan) RC 51 No data 92% with underlying conditions 33.3% (17/51) (PD) d90 58% 
1 year after diagnosis or induction treatment 
Chen (2012)[11] HIC (Australia) RC 73 CG 28% with underlying conditions 13% (10/73) (PD) 68% 
                                                          
c No 95% CI presented if not available 
d PD: Mortality expressed as a Percentage of Death at the time point (lost to follow-up excluded when known), or  
SA: Survival Analysis (probability of mortality at a time point, lost to follow-up censored) 
 36 
 
Phillips 
(2015)[34] 
HIC (Canada) RC 47 CG 45% with underlying conditions 27.7% (13/47) (PD) 64% 
Zhu (2010)[32] LMIC (China) RC 154 No data 33% with underlying conditions 28.7% (41/143) (PD) 62% 
Liao (2012)[23] HIC (Taiwan) RC 53 No data 100% with underlying conditions 42.3% (22/52) (PD) 54% 
RCT: Randomized Control Trial, PC: Prospective Cohort, RC: Retrospective Cohort. 
HIC: High Income Countries LMIC: Low and Middle Income Countries 
D90: at day 90 after diagnosis or induction treatment; D120: at day 120 after diagnosis or induction treatment
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Table 3: HIV-CM predictive factors of long-term mortality identified by the review 
Predictive factors Number 
of 
studies 
Studies Design 
Quality 
score 
Outcome measure of association (95%CI) and/or p-value if 
informed by the authors 
Protective factors 
ART vs no ART at induction 2 Mathiesen (2012)[24]  
Lanoy (2011)[22] 
RC 81% 
PC 69% 
Rate Ratio ag (Cox) for 1 year mortality=0.22 (0.06-0.77) p=0.018 
1-year mortality (Kaplan-Meier) in pre-ART = 50% (45-54) vs 17% 
(12-22) in late-ART 
Early ART initiation vs late 
ART initiation after induction 
(for ART naïve patients) 
2 Boulware (2014)[20] 
 
Makadzange 
(2010)[28] 
RCT 82% 
 
RCT 50% 
ART initiation at 2 wks vs 5 wks: HRe (Cox) for 11 months 
mortality = 1.66 (1.03-2.68) p=0.04 
ART initiation at <72h vs 10 wks: HRaf (Cox) for 3 years mortality 
= 2.85 (1.1-7.23) p=0.031 
                                                          
e
 Not adjusted because RCT with similar characteristic in both arms (p>0.1 for all characteristics) 
f
 Adjusted on age, sex, CSF CrAG titer, CD4 level 
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AmB based bitherapy vs 
monotherapy 
 
 
 
1 Day (2013)[16] 
 
 
 
Bicanic (2008)[19] 
RCT 82% 
 
 
 
RCT 55% 
AmB+5FC vs AmB: HRai (Cox) for 6 months mortality = 0.56 
(0.36-0.87) p=0.01 
AmB+5FC vs AmB+Fluconazole: HRai (Cox) for 6 months 
mortality = 0.55(0.35-0.88) p=0.01 
AmB 0.7mg/kg vs AmB 1 mg/Kg (+ 5FC) for 6 months and 12 
months mortality: no difference (Fisher exact test – no data 
neither p-value given) 
Risk factors 
Older Age 1 Mathiesen (2012)[24] RC 81% Rate Ratio ag (Cox) for 1 year mortality for each year increase (in 
age) = 1.05 (0.99-1.11) p=0.054 
Altered neurology at 
induction vs no altered 
2 Chaiwarith (2014)[25] RC 65% Orah (Logistic) for 1 year mortality = 5.27 (1.26-24.05) 
                                                          
g
 Variables included in the model: age, sex, mental status, CD4, time-updated initiation of ART, antifungal regimen, flucytosine induction, nationality, time-period (88-96/97-08), hospital centre 
(variables with p<0.1 were included in the model) 
h
 Variables included in the model (with p<0.10 in univariate) are altered mental status, seizures, CSF CrAg titer, year of diagnosis (2005-2010) 
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neurology (with different 
items according to studies) 
 
Day (2013)[16] 
 
RCT 82% 
 
HRai (Cox) for 6 months mortality =2.30(1.57-3.36) p<0.001 
Baseline elevated fungal 
burden (CSF CrAg titres or 
fungal load) 
2 
 
 
Chaiwarith (2014)[25] 
 
Day (2013)[16] 
RC 65% 
 
RCT 82% 
ORalh (Logistic) elevated CrAg for 1 year mortality = 7.08 (1.62-
31) 
HRai (Cox) elevated fungal load for 6 months mortality=1.33 
(1.08-1.65) p=0.01 for each increase of 1 log10 CFU/mm3 
                                                          
i
 Adjusted on Age, Sex, Headache, Fever, Neck stiffness, Seizure, Glasgow coma score, Cranial-nerve palsy, papilledema, CSF opening pressure>18 cm H2O, CSF WCC, CSF glucose, plasma glucose 
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Low CD4 at induction (<20 
vs >20) 
1 Liao (2012)[23] RC 54% ORaj (Logistic) for > 1 year death or relapse=18(1.19-71.46) 
p=0.037  
Contradictory results  
IRIS vs no IRIS during the CM 
episode 
3 Boulware (2010)[30] 
Bicanic (2009)[29] 
 
Boulware (2014)[20] 
PC 77% 
PC 54% 
 
RCT 82% 
HRak (Cox) for 1 year mortality = 2.3(1.1-1.51) p=0.04 
No association (Fisher exact test) as 36% of 6-months mortality 
in IRIS vs 26% in non-IRIS, p=0.49 
IRIS in early ART vs late ART: 20% [17/87] and 13% [9/69], 
respectively, p=0.32 (while mortality significantly higher in early 
ART) 
Evidence based on multivariate analysis 
Evidence based on univariate analysis 
                                                          
j
 Variables included in the model: clinical, laboratory variables at presentation + antifungal treatment given.  
k
 Adjusted on baseline CD4, all other characteristic similar in both groups (BMI, time from CM to ART, Opportunistic infection, Baseline CD8, Baseline and subsequent VL, subsequent CD4, Eosinophils, 
initial serum CrAG titer median) 
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PC: Prospective Cohort, RC: Retrospective Cohort, RCT: Randomized Control Trial
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Table 4: Non-HIV-CM predictive factors of long-term mortality identified by the review 
Predictive factors Number 
of 
studies 
Studies Design 
Quality 
score 
Outcome measure of association (95%CI) and/or p-value if 
informed by the authors 
Protective factors 
AmB based therapy 
 
 
 
2 Zhu (2010)[32] 
 
Sun (2009)[51] 
 
RC 62% 
 
PC 69% 
Non AmB-based vs AmB based: HRa
l
 (Cox) for 1-year mortality = 
8.87(3.53-22.25) p<0.001 
AmB lipid vs AmB deoxylate: Ora
n
 (Logistic) for 3 months 
mortality=0.11(0.02-0.57) p=0.008 
Risk factors 
Delayed diagnosis vs no delayed 1 Zhu (2010)[32] RC 62% HRa
l
 (Cox) = 6.3(2.41-16.53) p<0.001 
Older Age 1 Zhu (2010)[32]  RC 62% No data shown 
                                                          
l
 Variables included in the model: age, sex, time to diagnosis>4months, pulmonary crypto, AID, hematological malignancy, solid malignancy, corticotherapy, transplantation, healthy, altered mental status, coma, seizure, 
cerebral herniation, non AmB based initial therapy, inclusion of 5FC, intrathecal AmB treatment, ommaya implantation 
 43 
 
Altered neurology at induction vs no 
altered neurology (with different 
definitions according to studies: 
focal neurologic signs, 
hydrocephalus, Low Glasgow score, 
herniation) 
3 Zhu (2010)[32] 
Liao (2012)[23] 
Chen (2012) C. 
gattii[11] 
RC 62% 
RC 54% 
RC 68% 
 HRa
l
 (Cox) = 8.08(2.96-16.95) p<0.001 
ORa
m
 (Logistic) for > 1 year death or relapse=8.7(2.23-28.98) p=0.003 
1 year mortality 19% in abnormal neuro vs 3% in normal neuro, (Fisher 
exact test) p=0.05 
Baseline elevated fungal burden 
(CSF CrAg titres) 
1 
 
Liao (2012)[23] 
 
Chen (2012) C.Gattii 
RC 54% 
 
RC 68% 
>1/512 vs <1/512: ORa
m
 (Logistic) for > 1 year death or 
relapse=16.2(1.37-192.02) p=0.027  
>1/256 vs <1/256: Ora for 1 year mortality=1.8(1–26) p=0,05 
Fungemia vs no fungemia in SOT 1 Sun (2009)[51] PC 69% ORa
n
 (Logistic) for 3 months mortality= 10.6 (2.08-54.55) p=0.004 
Renal failure vs no renal failure in 
SOT 
1 Sun (2009) [51] PC 69% ORa
n
 (Logistic) for 3 months mortality= 4.61(1.02-20.8) p=0.047 
Contradictory results  
                                                          
m
 Variables included in the model: clinical, laboratory variables at presentation + antifungal treatment given. 
n
 Variables included in the model (with p<0.20 in univariate) are CNIs, renal failure at baseline, abnormal mental status, fungemia, receipt of lipid AmB (backward strategy) 
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Underlying conditions vs healthy 2 Chen (2012) C Gattii 
[11] 
Zhu (2010)[32]  
 
RC 68%  
 
RC 62% 
 
1 year mortality 26% in predisposed vs 7.4% in healthy (Log-rank test) 
p=0.03 
1-year mortality 26.5% in predisposed vs 29.8% in healthy (Fisher exact 
test) p=0.69 
 
Evidence based on multivariate analysis 
Evidence based on univariate analysis 
PC: Prospective Cohort, RC: Retrospective Cohort, RCT: Randomized Control Trial, SOT: Solid Organ Transplant 
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FIGURES:  
Figure 1: Flow diagram of the article inclusion/exclusion process (inspired from PRISMA 2009 Flow Diagram[14]). 
Figure 2: Forest plot of proportion of one-year mortality in HIV-CM according to induction therapy received. 
Legends of figure 2:  
4 studies are excluded from this forest plot: 
- Boulware et al (2010) study because the mortality is probably under-estimated[30]. The patients were included after ART initiation at a median time from CM diagnosis of 34 days (IQR: 24-
41), missing all death happening during the first weeks.  
- Lanoy et al (2011)[22], Liao et al (2012)[23] and Mathiesen et al (2012)[24] because no information was available or extractable for the treatment received by the patients infected by HIV or 
for the dichotomised periods. 
 
In the Bicanic 2007 study[26], 92% of patients were treated by AmB monotherapy and 8% of patients were treated by fluconazole monotherapy. 
 
 46 
 
Figure 1 
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Figure 2 
 
 
 
